Multivariable analysis incorporating individual ctDNA mutations, clinical factors, IGH rearrangements, del(17p), and plasma DNA concentration
| Variable . | Coefficient . | HR . | 95% lower CI . | 95% upper CI . | P value . |
|---|---|---|---|---|---|
| KRAS mutation (ctDNA-seq) | 1.1 | 3.1 | 1.7 | 5.7 | 1.8 × 10−4 |
| TP53 mutation (ctDNA-seq) | 0.7 | 2.0 | 1.3 | 3.1 | .0023 |
| ATM mutation (ctDNA-seq) | 1.3 | 3.8 | 1.6 | 9.1 | .0028 |
| t(11;14) (FISH) | 0.7 | 2.0 | 1.2 | 3.3 | .0065 |
| No. of prior regimens, n ≥ 3 | 1.1 | 2.9 | 1.7 | 5.1 | 1.5 × 10−4 |
| No. of prior regimens, n = 2 | 0.6 | 1.7 | 0.9 | 3.2 | .078 |
| Plasma DNA concentration: high | 0.6 | 1.8 | 1.2 | 2.7 | .0084 |
| Variable . | Coefficient . | HR . | 95% lower CI . | 95% upper CI . | P value . |
|---|---|---|---|---|---|
| KRAS mutation (ctDNA-seq) | 1.1 | 3.1 | 1.7 | 5.7 | 1.8 × 10−4 |
| TP53 mutation (ctDNA-seq) | 0.7 | 2.0 | 1.3 | 3.1 | .0023 |
| ATM mutation (ctDNA-seq) | 1.3 | 3.8 | 1.6 | 9.1 | .0028 |
| t(11;14) (FISH) | 0.7 | 2.0 | 1.2 | 3.3 | .0065 |
| No. of prior regimens, n ≥ 3 | 1.1 | 2.9 | 1.7 | 5.1 | 1.5 × 10−4 |
| No. of prior regimens, n = 2 | 0.6 | 1.7 | 0.9 | 3.2 | .078 |
| Plasma DNA concentration: high | 0.6 | 1.8 | 1.2 | 2.7 | .0084 |
HRs for PFS evaluated by Cox PH model incorporating the presence of KRAS, TP53, DIS3, BRAF, NRAS, and ATM ctDNA mutations and clinical factors (treatment indication and number of prior therapies), IGH rearrangements (by FISH), 17p deletion (by BMPC-seq), and plasma DNA concentration in 161 RRMM cases analyzed by both ctDNA-seq and BMPC-seq.
High and low plasma DNA concentration by a median split. Final Cox PH model after stepwise variable selection minimizing Akaike’s information criterion are shown.
CI, confidence interval; HR, hazard ratio.